CY1106769T1 - Λυοφιλοποιησιμη φαρμακευτικη συνθεση εικονικου φαρμακου προοριζομενη για τη μιμηση ενος φαρμακου, ειδικα με βαση πρωτεϊνες ή πολυπεπτιδια - Google Patents

Λυοφιλοποιησιμη φαρμακευτικη συνθεση εικονικου φαρμακου προοριζομενη για τη μιμηση ενος φαρμακου, ειδικα με βαση πρωτεϊνες ή πολυπεπτιδια

Info

Publication number
CY1106769T1
CY1106769T1 CY20071101005T CY071101005T CY1106769T1 CY 1106769 T1 CY1106769 T1 CY 1106769T1 CY 20071101005 T CY20071101005 T CY 20071101005T CY 071101005 T CY071101005 T CY 071101005T CY 1106769 T1 CY1106769 T1 CY 1106769T1
Authority
CY
Cyprus
Prior art keywords
drug
pharmaceutical
pharmaceutical composition
lyophilisable
simulation
Prior art date
Application number
CY20071101005T
Other languages
English (en)
Inventor
Annie Bardat
Roland Schmitthauesler
Original Assignee
Laboratoire Français Du Fractionnement Et Des Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Français Du Fractionnement Et Des Biotechnologies filed Critical Laboratoire Français Du Fractionnement Et Des Biotechnologies
Publication of CY1106769T1 publication Critical patent/CY1106769T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αφορά μία λυοφιλοποιημένη φαρμακευτική σύνθεση προοριζόμενη για τη μίμηση ενός φαρμάκου, ειδικά με βάση πρωτεΐνες ή πεπτίδια, και η οποία μπορεί να χρησιμεύσει ως εικονικό φάρμακο, χαρακτηριζόμενη από το ότι περιλαμβάνει το σύνηθες έκδοχο του εν λόγω φαρμάκου, μία ή περισσότερες σακχαρο-αλκοόλες υπό κρυσταλλική μορφή και/ή ένα ή περισσότερα αμινοξέα υπό κρυσταλλική μορφή, η οποία σύνθεση παρουσιάζει ωσμωτικότητα περιλαμβανόμενη μεταξύ 250 και 650 mOsm μετά από ανασύσταση υπό τη μορφή διαλύματος. Εφαρμογή στις ενέσιμες μορφές ή σε διαδερμική ή οφθαλμική εφαρμογή.
CY20071101005T 1997-09-18 2007-07-30 Λυοφιλοποιησιμη φαρμακευτικη συνθεση εικονικου φαρμακου προοριζομενη για τη μιμηση ενος φαρμακου, ειδικα με βαση πρωτεϊνες ή πολυπεπτιδια CY1106769T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9711626A FR2768341B1 (fr) 1997-09-18 1997-09-18 Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
PCT/FR1998/001956 WO1999013866A1 (fr) 1997-09-18 1998-09-14 Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides

Publications (1)

Publication Number Publication Date
CY1106769T1 true CY1106769T1 (el) 2012-05-23

Family

ID=9511216

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101005T CY1106769T1 (el) 1997-09-18 2007-07-30 Λυοφιλοποιησιμη φαρμακευτικη συνθεση εικονικου φαρμακου προοριζομενη για τη μιμηση ενος φαρμακου, ειδικα με βαση πρωτεϊνες ή πολυπεπτιδια

Country Status (11)

Country Link
US (1) US6242423B1 (el)
EP (1) EP1014948B1 (el)
AT (1) ATE365542T1 (el)
CA (1) CA2304021A1 (el)
CY (1) CY1106769T1 (el)
DE (1) DE69837997T2 (el)
DK (1) DK1014948T3 (el)
ES (1) ES2287980T3 (el)
FR (1) FR2768341B1 (el)
PT (1) PT1014948E (el)
WO (1) WO1999013866A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768341B1 (fr) * 1997-09-18 2000-04-14 Lab Francais Du Fractionnement Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
US6566575B1 (en) 2000-02-15 2003-05-20 3M Innovative Properties Company Patterned absorbent article for wound dressing
US6977323B1 (en) 2000-02-17 2005-12-20 3M Innovative Properties Company Foam-on-film medical articles
US6716186B1 (en) 2000-08-16 2004-04-06 3M Innovative Properties Company Curable adhesive splints and methods
US6903243B1 (en) 2000-09-08 2005-06-07 3M Innovative Properties Company Multi-layer absorbent wound dressing
US7005143B2 (en) 2002-04-12 2006-02-28 3M Innovative Properties Company Gel materials, medical articles, and methods
US7612248B2 (en) 2002-12-19 2009-11-03 3M Innovative Properties Company Absorbent medical articles
US20050070688A1 (en) 2003-09-26 2005-03-31 3M Innovative Properties Company Reactive hydrophilic oligomers
US7384984B2 (en) 2003-12-10 2008-06-10 3M Innovative Properties Company Reactive hydrophilic oligomers
US7074839B2 (en) 2004-03-01 2006-07-11 3M Innovative Properties Company Crosslinkable hydrophilic materials from reactive oligomers having pendent photoinitiator groups
US7342047B2 (en) * 2004-03-02 2008-03-11 3M Innovative Properties Company Crosslinkable hydrophilic materials from reactive oligomers having pendent unsaturated groups
US7335690B2 (en) 2005-01-25 2008-02-26 3M Innovative Properties Company Crosslinkable hydrophilic materials from polymers having pendent Michael donor groups
US8609131B2 (en) 2005-01-25 2013-12-17 3M Innovative Properties Company Absorbent dressing comprising hydrophilic polymer prepared via Michael reaction
US7981949B2 (en) 2006-05-23 2011-07-19 3M Innovative Properties Company Curable hydrophilic compositions
US20110155620A1 (en) 2009-12-30 2011-06-30 Baxter International Inc. Rapid reconstitution for lyophilized-pharmaceutical suspensions
WO2023183542A2 (en) * 2022-03-25 2023-09-28 Amgen Inc. Artificial lyophilized product samples for automated visual inspection systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5151511A (en) * 1974-10-25 1976-05-07 Tooru Tatsuhara Aminosanseizai no anteikaho
EP0084705B1 (en) * 1981-12-11 1987-01-14 JOHN WYETH & BROTHER LIMITED Process for preparing solid shaped articles
IL78930A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
FR2751177B1 (fr) * 1996-07-17 1998-08-28 Morelle Jean Compositions exemptes de proteines et de peptides obtenues a partir de toutes proteines animales, destinees a l'alimentation animale et humaine, ainsi qu'a l'usage cosmetique pharmaceutique et agricole
FR2768341B1 (fr) * 1997-09-18 2000-04-14 Lab Francais Du Fractionnement Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides

Also Published As

Publication number Publication date
DE69837997D1 (de) 2007-08-09
ES2287980T3 (es) 2007-12-16
DE69837997T2 (de) 2008-02-28
FR2768341A1 (fr) 1999-03-19
EP1014948B1 (fr) 2007-06-27
FR2768341B1 (fr) 2000-04-14
EP1014948A1 (fr) 2000-07-05
PT1014948E (pt) 2007-07-18
DK1014948T3 (da) 2007-09-24
US6242423B1 (en) 2001-06-05
WO1999013866A1 (fr) 1999-03-25
CA2304021A1 (fr) 1999-03-25
ATE365542T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
CY1106769T1 (el) Λυοφιλοποιησιμη φαρμακευτικη συνθεση εικονικου φαρμακου προοριζομενη για τη μιμηση ενος φαρμακου, ειδικα με βαση πρωτεϊνες ή πολυπεπτιδια
CY1106995T1 (el) Αμφιφιλα λιπιδικα νανοσωματιδια για ενσωματωση σε πεπτιδιο ´η/και πρωτεïνη
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
PT97159A (pt) Processo para a preparacao de uma proteina do antigenio de superficie da hepatite b ou de um seu fragmento e processo para a preparacao de uma vacina
ATE410441T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen
DE69312947T2 (de) Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
DE69327057T2 (de) Polyarylate, die derivate der natürlichen aminosäure l-tyrosin enthalten
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
DE69840195D1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
CY1105604T1 (el) Μεθοδος ενισχυσης ανοσων απαντησεων στο εμβολιο κατα του ιου του απλου ερπητα
BR9106220A (pt) Antigenos sinteticos para a deterccao de anticorpos para o virus da hepatite c.
DE69129865T2 (de) Osteogene peptide
SE9403526D0 (sv) New Peptides
ES2118939T3 (es) Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi.
ATE193022T1 (de) Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
CO5570658A2 (es) Composicion y metodo para el tratamiento de la diabetes
DK0491628T3 (da) Lipopeptider inducerende cytotoksiske T-lymfocytter og deres anvendelse som vacciner
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
TR199902575T2 (xx) Peptitler, proteinler ve nükleik asitler için stabil farmasötik uygulama formu.
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
LV11816A (lv) Implantejama zalu forma
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
NO942707L (no) Syntetiske peptider egnet for vaksine mot rubellsinfeksjoner